A meta‐analysis comparing 23 first‐line treatment regimens in HER2‐negative advanced GC demonstrated that, compared to the PF regimen (cisplatin and fluorouracil), the combination of XELOX (Capecitabine and Oxaliplatin) with sintilimab (a PD‐1 inhibitor) or SOX (S‐1 and Oxaliplatin) with nivolumab (another PD‐1 inhibitor) significantly improved overall survival (OS) [27]. Here, ERBB2 is linked to gastric cancer.